共 46 条
[1]
Li JQ(2020)Prevalence and incidence of age-related macular degeneration in Europe: a systematic review and meta-analysis Br J Ophthalmol 104 1077-1084
[2]
Welchowski T(2022)Neovascular age-related macular degeneration (nAMD): a review of emerging treatment options Clin Ophthalmol 16 917-933
[3]
Schmid M(2022)Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials Lancet Lond Engl 399 729-740
[4]
Tan CS(2023)The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study–6 month results Eye 37 3574-3581
[5]
Ngo WK(2023)Initial real-world experience with faricimab in treatment-resistant neovascular age-related macular degeneration Clin Ophthalmol Auckl NZ 17 1287-1293
[6]
Chay IW(2023)Short-term outcomes of intravitreal faricimab for treatment-naïve neovascular age-related macular degeneration Graefes Arch Clin Exp Ophthalmol 261 2945-2952
[7]
Heier JS(2023)Faricimab in neovascular AMD: first report of real-world outcomes in an independent retina clinic Eye 37 3282-3289
[8]
Khanani AM(2022)Intravitreal faricimab for aflibercept-resistant neovascular age-related macular degeneration Clin Ophthalmol Auckl NZ 16 4041-4046
[9]
Quezada Ruiz C(2023)Faricimab effectively resolves intraretinal fluid and preserves vision in refractory, recalcitrant, and nonresponsive neovascular age-related macular degeneration Cureus 15 e40100-1895
[10]
Khanani AM(2021)TENAYA and LUCERNE: rationale and design for the phase 3 clinical trials of faricimab for neovascular age-related macular degeneration Ophthalmol Sci 1 100076-1596